These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 15150206)

  • 1. Pharmacy benefits and the use of drugs by the chronically ill.
    Goldman DP; Joyce GF; Escarce JJ; Pace JE; Solomon MD; Laouri M; Landsman PB; Teutsch SM
    JAMA; 2004 May; 291(19):2344-50. PubMed ID: 15150206
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Employer drug benefit plans and spending on prescription drugs.
    Joyce GF; Escarce JJ; Solomon MD; Goldman DP
    JAMA; 2002 Oct; 288(14):1733-9. PubMed ID: 12365957
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adverse events associated with prescription drug cost-sharing among poor and elderly persons.
    Tamblyn R; Laprise R; Hanley JA; Abrahamowicz M; Scott S; Mayo N; Hurley J; Grad R; Latimer E; Perreault R; McLeod P; Huang A; Larochelle P; Mallet L
    JAMA; 2001 Jan 24-31; 285(4):421-9. PubMed ID: 11242426
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of cost sharing on prescription drugs used by Medicare beneficiaries.
    Goedken AM; Urmie JM; Farris KB; Doucette WR
    Res Social Adm Pharm; 2010 Jun; 6(2):100-9. PubMed ID: 20511109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of mail-service and retail community pharmacy claims in 5 prescription benefit plans.
    Clark BE; Siracuse MV; Garis RI
    Res Social Adm Pharm; 2009 Jun; 5(2):133-42. PubMed ID: 19524861
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Labour productivity effects of prescribed medicines for chronically ill workers.
    Rizzo JA; Abbott TA; Pashko S
    Health Econ; 1996; 5(3):249-65. PubMed ID: 8817299
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of an annual dollar limit or "cap" on prescription drug benefits for Medicare patients.
    Tseng CW; Brook RH; Keeler E; Mangione CM
    JAMA; 2003 Jul; 290(2):222-7. PubMed ID: 12851277
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacy benefit caps and the chronically ill.
    Joyce GF; Goldman DP; Karaca-Mandic P; Zheng Y
    Health Aff (Millwood); 2007; 26(5):1333-44. PubMed ID: 17848444
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of type 2 diabetes medication cost sharing on patient outcomes and health plan costs.
    Thornton Snider J; Seabury S; Lopez J; McKenzie S; Goldman DP
    Am J Manag Care; 2016 Jun; 22(6):433-40. PubMed ID: 27355811
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Varying pharmacy benefits with clinical status: the case of cholesterol-lowering therapy.
    Goldman DP; Joyce GF; Karaca-Mandic P
    Am J Manag Care; 2006 Jan; 12(1):21-8. PubMed ID: 16402885
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The association of consumer cost-sharing and direct-to-consumer advertising with prescription drug use.
    Hansen RA; Schommer JC; Cline RR; Hadsall RS; Schondelmeyer SW; Nyman JA
    Res Social Adm Pharm; 2005 Jun; 1(2):139-57. PubMed ID: 17138472
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-lowering strategies used by medicare beneficiaries who exceed drug benefit caps and have a gap in drug coverage.
    Tseng CW; Brook RH; Keeler E; Steers WN; Mangione CM
    JAMA; 2004 Aug; 292(8):952-60. PubMed ID: 15328327
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of health plan design and management on retirees' prescription drug use and spending, 2001.
    Thomas CP; Wallack SS; Lee S; Ritter GA
    Health Aff (Millwood); 2002; Suppl Web Exclusives():W408-19. PubMed ID: 12703602
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of drug plans on adherence to and the cost of antihypertensive medications among patients covered by a universal drug insurance program.
    Després F; Perreault S; Lalonde L; Forget A; Kettani FZ; Blais L
    Can J Cardiol; 2014 May; 30(5):560-7. PubMed ID: 24613090
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Unintended consequences of caps on Medicare drug benefits.
    Hsu J; Price M; Huang J; Brand R; Fung V; Hui R; Fireman B; Newhouse JP; Selby JV
    N Engl J Med; 2006 Jun; 354(22):2349-59. PubMed ID: 16738271
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Medical Costs and Health Care Utilization Among Self-Insured Members with Carve-In Versus Carve-Out Pharmacy Benefits.
    Smith JJ; Qiu Y; Lam SV; Lockwood CM; Pegus C; Gleason PP
    J Manag Care Spec Pharm; 2020 Jun; 26(6):766-774. PubMed ID: 32154745
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient and Plan Spending after State Specialty-Drug Out-of-Pocket Spending Caps.
    Yeung K; Barthold D; Dusetzina SB; Basu A
    N Engl J Med; 2020 Aug; 383(6):558-566. PubMed ID: 32757524
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Managing prescription drug costs.
    Sica JM
    Empl Benefits J; 2001 Mar; 26(1):35-40. PubMed ID: 11272515
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of a three-tier formulary on antidepressant utilization and expenditures.
    Hodgkin D; Parks Thomas C; Simoni-Wastila L; Ritter GA; Lee S
    J Ment Health Policy Econ; 2008 Jun; 11(2):67-77. PubMed ID: 18509214
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost sharing, caps on benefits, and the chronically ill--a policy mismatch.
    Thorpe KE
    N Engl J Med; 2006 Jun; 354(22):2385-6. PubMed ID: 16738277
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.